

Seeking Druggable Targets in Progressive Fibrosing Interstitial Lung Disease or Pulmonary Hypertension



Johnson & Johnson, a global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations, wishes to identify druggable targets in progressive fibrosing interstitial lung disease (PF-ILD), idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).

Research Interests

1. IPF/PF-ILDs

- Opportunities that offer the potential for clinical translation
- Mechanism of actions that reduce fibrosis by targeting TGF- β signalling without the risk of inflammation, target activation, function of myofibroblast/fibroblast or enhance tissue regeneration

2. Pulmonary Hypertension

- Pulmonary hypertension all groups (Group 1-5) are within scope, with a particular interest in groups 1 and 3
- Opportunities that offer the potential for clinical translation
- Mechanisms of actions that target vascular remodelling, senescence or proliferation with a link to human disease (protein, mRNA etc)

Developmental Stages of Interest

- Research at basic level through to clinical phase II is within scope
- Validation through cell or animal models is encouraged

Out of Scope

- Agents for IPF/PF-ILD that primarily act via targeting ROS, inflammation or non-specific TGF β inhibition that would be predicted to result in inflammation
- Agents for PH that act primarily through vasodilation and/or coagulation


Jurisdictions of Interest

Only submissions from universities and research institutions in Europe, Africa and the Middle East will be considered.

Submission Information

Submission of one-page research briefs (approx 200 - 300 words) plus any extra applicable information is encouraged.

Opportunities sought

-  Spinout companies
-  Research projects
-  Centres of excellence
-  Academics and expertise
-  Technologies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **25th January 2021 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk